原发性部分腺体冷冻消融后3年肿瘤控制活检评估:中危前列腺癌男性的前瞻性队列研究
前瞻性队列纳入2017年3月起接受原发性部分腺体冷冻消融的单侧中危前列腺癌男性,术后2年行监测活检并对高复发 suspicion 者行反射活检;132例随访≥24个月,活检发现12例临床显著前列腺癌,36个月模型估计总体无复发率86%(95%CI 78-93),无失败率97%(95%CI 93-100)。
要点
- 36个月模型估计野内、野外和总体临床显著癌无复发率分别为97%、87%和86%。
- 36个月模型估计无失败比例为97%(95%CI 93-100)。
- 术后2年监测活检发现12例临床显著前列腺癌,需长期监测。
核心结论
- 3年野内癌检出率低提示局部癌消融成功,但野外检出率凸显部分腺体冷冻消融后需持续监测。
- 许多复发临床显著病变体积很小,低于多参数MRI检出阈值,提示多参数MRI在2年时检出临床显著复发的作有限。
- 作者认为这些发现强调需长期监测并识别临床显著前列腺癌复发的预测因素以指导活检时机。
研究设计与样本
- 前瞻性结局登记研究,纳入2017年3月起接受原发性部分腺体冷冻消融的单侧中危前列腺癌男性。
- 所有男性术后方案包括消融后2年监测前列腺活检,并对高复发 suspicion 病例(如PSA进行性升高)行反射前列腺活检。
- 临床显著前列腺癌复发定义为消融后活检任何Gleason分级分组≥2疾病。
- 无失败定义为无全腺体挽救治疗、无转移性前列腺癌或无前列腺癌死亡。
- 共132例男性有至少24个月随访数据。
主要发现
- 活检发现12例临床显著前列腺癌。
- 36个月模型估计野内临床显著癌无复发率为97%(95%CI 92-100)。
- 36个月模型估计野外临床显著癌无复发率为87%(95%CI 80-94)。
- 36个月模型估计总体临床显著癌无复发率为86%(95%CI 78-93)。
- 36个月模型估计无失败比例为97%(95%CI 93-100)。
临床怎么用
- 原文结论认为,3年野内癌检出率低提示局部癌消融成功。
- 原文结论认为,观察到的野外检出率凸显部分腺体冷冻消融后需持续监测。
- 作者认为许多复发临床显著病变体积很小、低于多参数MRI检出阈值,提示多参数MRI在2年时检出临床显著复发的作有限。
- 作者认为这些发现强调需长期监测并识别临床显著前列腺癌复发的预测因素以指导活检时机。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated 3-year oncologic outcomes following primary partial gland cryoablation. MATERIALS AND METHODS: Men with unilateral intermediate-risk prostate cancer undergoing primary partial gland cryoablation since March 2017 enrolled in a prospective outcome registry. The postablation protocol for all men included surveillance prostate biopsy at 2 years postablation and reflex prostate biopsy for cases with high suspicion of recurrence (eg, progressive rise in PSA). Recurrence of clinically significant prostate cancer was defined as any Gleason grade group ≥2 disease on postablation biopsy. Freedom from failure represented no whole gland salvage treatment, metastatic prostate cancer, or prostate cancer mortality. Freedom from recurrence and freedom from failure were characterized using nonparametric maximum likelihood estimators. RESULTS: A total of 132 men had at least 24 months of follow-up data. Biopsies identified clinically significant prostate cancer in 12 men. At 36 months, model-estimated rates of freedom from recurrence of in-field, out-of-field, and overall clinically significant cancer were 97% (95% CI: 92-100), 87% (95% CI: 80-94), and 86% (95% CI: 78-93), respectively. The model-estimated proportion with freedom from failure at 36 months was 97% (95% CI: 93-100). CONCLUSIONS: The low in-field cancer detection rate at 3 years indicates successful ablation of localized cancers. Conversely, our observed out-of-field detection rate highlights the need for continued surveillance following partial gland cryoablation. Many of these recurrences exhibited very low volume of clinically significant disease below the detection threshold of multiparametric MRI, suggesting a limited role for multiparametric MRI in detecting clinically significant recurrences at 2 years. These findings emphasize the need for long-term surveillance and identification of predictors of clinically significant prostate cancer recurrences to guide biopsy timing.
引用
- Wysock JS, Rapoport E, Hernandez H, et al. Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-risk Prostate Cancer. J Urol. 2023. PMID: 37285232. doi:10.1097/JU.0000000000003569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。